<DOC>
	<DOCNO>NCT01781988</DOCNO>
	<brief_summary>Excision repair cross complement 1 ( ERCC1 ) ribonucleotide reductase M1 ( RRM1 ) thymidylate synthase ( TS ) molecular determinant predict sensitivity resistance platinum agent 、 gemcitabine pemetrexed respectively . Tailored therapy use molecular determinant suggest patient benefit previously report phase 2 trial . Here , design study individual patient analysis prospectively accrued patient treat `` personalized therapy '' approach versus standard approach .</brief_summary>
	<brief_title>Personalized Therapy Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Patients nonsmall- cell lung cancer ( NSCLC ) performance status 0/1 accrue 2 phase 2 clinical trial Trial A ( carboplatin chemotherapy individuation base sensitivity marker ) , Trial B ( carboplatin non-individuation chemotherapy non-individuation ) . Patients treated Trials B analyze `` standard therapy '' group . Patients accrue Trial A call `` personalized therapy '' group . disease free survival ( DFS ) estimate use Kaplan-Meier method .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically confirm nonsmall cell lung cancer 2. age 18 year 75 year 3 . ECOG Performance Status 2 4. least one appraisable lung focus diameter≥ 10 mm lung CT 5 . Haemoglobin ≥10.0 g/dl , Absolute neutrophil count ≥ ( ANC ) 1.5 x 109/L , platelet ≥100 x 109/L 6 . Total bilirubin ≤1.5 x upper limit normal ( ULN ) 7 . ALT AST &lt; 2.5 x ULN absence liver metastasis , &lt; 5 x ULN case liver metastases 8 . Creatinine clearance ≥60ml/min ( calculate accord Cockcroftgault formula ) 9 . Informed consent obtain treatment . 1 . Mixed nonadenocarcinoma cell lung cancer histology 2 . Previous treatment Systemic chemotherapy local radiotherapy 3 . Be allergic chemotherapy drug 4. second active primary malignancy serious concomitant medical disease 5. difficulty adequate followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>carboplatin</keyword>
	<keyword>pemetrexed</keyword>
</DOC>